A record of what Nuvama Analysis said publicly, with the source. Not advice.
“Upgraded Dr Reddy's to 'Buy' from 'Reduce' with a target price of ₹1,553, valuing the stock at 24x FY27E EPS. The brokerage is optimistic about the company's proactive strategies to mitigate approximately 80% of the EBITDA fallout from the Revlimid patent expiration in 2026, despite the drug accounting for about 40% of FY24 EBITDA. This leads to a 15% increase in FY27E earnings forecasts, presenting a favorable risk-reward.”
Nuvama Analysis’s track record (trackable calls only): 161 graded calls · 95% CI 35–50%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹1,553, as stated.
Window: 12 months, the default when no time frame is stated.
Neither the target ₹1,553 was reached on a close by the end of the window. Miss.
The grader’s working: R4 TARGET_CALL: entered ₹1371.6 on 2025-01-09 (next trading session's close); neither target nor stop reached by window end 2026-01-08. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.